2172. Tuberculosis and HIV coinfection in hospitalized Colombian patients
Session: Poster Abstract Session: HIV: Other Opportunistic Conditions
Saturday, October 29, 2016
Room: Poster Hall
  • TB poster.pdf (1.2 MB)
  • Background: Patients with HIV have between 20 and 37 times greater risk of tuberculosis. Concomitant treatment of latent tuberculosis (TB) infection with early highly active antiretroviral therapy (HAART) in high prevalence countries helped decrease HIV-associated infections by 44% and mortality decreased by 35%.

    Methods: Descriptive study including patients admitted with TB/HIV at six hospitals in Medellin, Colombia, where data were prospectively collected for one year.

    Results: 128 HIV/TB infected patients were admitted: 79.7% were male with a mean age of 38.4 years (standard deviation 11.3). De novo HIV diagnosis was made in 28.9%. At the time of admission 47% of patients were on HAART and 35% were adherent. 85.2% of patients had CD4 counts less than 200 CD4 cells/uL and 68.8 had HIV viral loads greater thas 100,000 copies/mL. 8.5% of patients had had tuberculin testing within the last year, 4 of the tuberculin tests were positive and only one was treated. 41.8% of patients had previously had TB, and of these only 13% were on HAART. Types of compromise with tuberculosis are depicted in table 1. The main concomitant opportunisitic infections were candidiasis (14.1%), histoplasmosis (11.7%) and toxoplasmosis (7.8%). Antituberculous medication toxicity occurred in 12.5%; 3.9% needed change in treatment. The mean hospital stay was 23.2 (SD +14.7) days, 14.8% of patients required admission to the ICU and 10.2% readmission, mortality was 5.5%


    Table 1: Types of compromise with tuberculosis.

    Type of tuberculosis

    N 128


    Only pulmonary TB

    44 (34.4)

    Extrapulmonary + pulmonary

    62 (48.4)

    Extrapulmonary (without pulmonary)

    22 (17.2)


    8 (6.3)


    3 (2.3)


    3 (2.3)


    6 (4.7)

    Others: bone, peritoneal, soft tissues, intestinal, pleura

    Conclusion: Sustainable strategies in order to implement and maintain LTBI diagnosis and treatment programs in HIV/TB coinfected patients, as well as programs enforcing the use and adherence to HAART are needed in developing countries where the burden of TB is high

    Maria Alvarez, Resident1, Juan Pablo Villa, Infectious disease resident2, Carlos Agudelo Restrepo, MD, MSc3, Alicia Hidron, MD, DTMH4, Lina Echeverri, MD5, Jaime Mauricio Ramirez, MD6, Adriana Ocampo, MD7, Glenys Porras, MD8, Ivan Trompa, MD9, Carlos Restrepo, MD, MSc10, Laura Restrepo, Medicine Student1 and Alejandro Eusse, Medicine Student1, (1)Universidad Pontificia Bolivariana, Medellin, Colombia, (2)Internal Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia, (3)Infectious Diseases, Clínica Universitaria Bolivariana Universidad Pontificia Bolivariana, Medellín, Colombia, (4)Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia, (5)Hospital San Vicente Fundación, Medellin, Colombia, (6)Hospital Universitario San Vicente Fundación, Medellin, Colombia, (7)Centros Especializados San Vicente Fundación, Rionegro, Colombia, (8)Hospital General de Medellin, Medellin, Colombia, (9)IPS Universitaria, Clínica León XIII, Medellin, Colombia, (10)Clinica Universitaria Pontificia Bolivariana, Medellin, Colombia


    M. Alvarez, None

    J. P. Villa, None

    C. Agudelo Restrepo, None

    A. Hidron, None

    L. Echeverri, None

    J. M. Ramirez, None

    A. Ocampo, None

    G. Porras, None

    I. Trompa, None

    C. Restrepo, None

    L. Restrepo, None

    A. Eusse, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.